About NOXXON
NOXXON’s oncology-focused pipeline breaks the tumor protection barrier and blocks tumor repair by neutralizing chemokines in the tumor micro-environment (TME). NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact.
After NOXXON’s lead program NOX-A12 delivered final top-line data with encouraging overall survival and safety profile from a combination trial with an anti-PD-1 immuno-oncology checkpoint inhibitor in metastatic colorectal and pancreatic cancer patients in September 2020, the company announced in July 2021 its upcoming Phase 2 study to further evaluate safety and efficacy of NOX-A12 in combination with anti-PD-1 and two different chemotherapy regimens as second-line therapy in patients with pancreatic cancer.
The combination of NOX-A12 and radiotherapy has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. An ongoing trial of NOX-A12 in combination with radiotherapy in newly diagnosed brain cancer patients who will not benefit from standard chemotherapy has delivered interim data from the low- and mid-dose cohorts showing consistent tumor reductions. The read-out from the third high-dose cohort is expected in early 2022.
The company’s second clinical-stage asset, NOX-E36 is a TME asset targeting the innate immune system and is planned to go back into the clinic in 2021. NOXXON plans to develop NOX-E36 in patients with solid tumors.
KOL Webinar with Dr. Frank Giordano on NOX-A12 & Radiotherapy Combination in Brain Cancer incl. Data Presented at the SNO Annual Meeting (November 2021) |
|
Press ReleaseBerlin, Germany
2022, May 19 08:00 a.m. NOXXON amends equity-linked facility with Atlas 2022, May 16 06:00 p.m. NOXXON announces results of the extraordinary general meeting of shareholders 2022, May 11 08:00 a.m. NOXXON appoints leading brain cancer experts to scientific advisory board |
EventsTIDES USA Oligonucleotide and Peptide Therapeutics
Aram Mangasarian Bio Equity Europe
Aram Mangasarian ASCO Annual Meeting
Aram Mangasarian, Avital Barak BIO International Convention
Aram Mangasarian 2nd Tumor Myeloid-Directed Therapies Summit
Anna Frömming |